Ask AI

Capsule Summaries

Share

Program Content

Activities

MK 8591A 052 Wk 96 DOR and ISL
MK-8591A-052 Week 96: Switch From BIC/FTC/TAF to DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 25, 2026

MK 8591A 051 Wk 96
MK-8591A-051 Wk 96: Switch From Standard-of-Care ART to DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 25, 2026

OPERA PrEP
OPERA Cohort: PrEP Coverage and HIV Incidence With LA CAB vs Daily Oral FTC/TDF or FTC/TAF
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

ARTISTRY-1
ARTISTRY-1: Phase III Trial of Single-Tablet BIC/LEN Switch vs Complex ART Continuation in People With HIV and Virologic Suppression
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

ARTISTRY-2
ARTISTRY-2: Phase III Trial of Single-Tablet BIC/LEN Switch vs BIC/FTC/TAF Continuation in People With HIV and Virologic Suppression
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

LEN Case Series
Case Series Evaluating Long-acting Lenacapavir in People With HIV and High Baseline Resistance
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

ANRS Prevenir
ANRS Prévenir: Final Results of Prospective Observational Cohort Study of Daily or On-Demand Oral FTC/TDF HIV PrEP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

MK-8527 PrEP
MK-8527 PrEP: Phase I-II PK Analysis to Inform Dosing for EXPrESSIVE Phase III Trial Program
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

LA CAB + RPV in Adolescents
IMPAACT 2017 Cohort 2: Wk 96 and End-of-Study Data After Switch to LA CAB + RPV in Adolescents Living With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

Lenacapavir PrEP in Adolescent and Young Women
PURPOSE 1: Long-term Follow-up of Twice-Yearly Lenacapavir PrEP in Adolescent and Young Women
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

Purpose 2 Longer Term Analysis
PURPOSE 2 Longer-Term Analysis: Phase III Trial of HIV PreP With Twice-Yearly LEN vs Daily FTC/TDF in Cisgender Men and Gender Diverse People
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

LEN Resistance Mutations in PURPOSE
PURPOSE 1 and PURPOSE 2: Randomized Blinded Phase Resistance Analysis With LEN PrEP
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

VOLITION
VOLITION Primary Analysis: Phase III Trial of Early LA CAB + RPV Switch After Achieving Virologic Suppression With DTG/3TC in Treatment-Naive Adults With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

EMBRACE
EMBRACE: 12 Mo Results With Lotivibart + LA CAB for People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare